الفهرس Only 14 pages are availabe for public view
 |  | from | 103 |  |  |
| | | from | 103 | | |
Abstract
In recent years cyclooxygenase 2 (COX - 2) inhibitors have been increasingly investigated for their potential to inhibit growth of solid tumors. COX-2 is a key enzyme in the conversion of arachidonic acid to prostaglandins, induced by in{uFB02}ammation and may play a role in the development of bladder cancer. Prostaglandin E2 (PGE2), the end product of COX - 2 - induced catalysis, autoamplifies the COX - 2 expression in solid tumors. It down regulates the apoptotic cascade PGE2 expression and COX - 2 activity is associated with cancer cachexia and tumorangiogenesis. The prominent clinical feature of cachexia is weight loss in adults or growth failure in children, anorexia, inflammation, insulin resistance, and increase muscle protein breakdown. The present work aims to clarify the pathogenesis of cachexia syndrome in cancer bladder patients and role may be played by cyclooxygenase 2 (COX2) and its metabolites prostaglandin E2 and PGF2Ü in occurrence of cachexia